BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Baxter AG submitted on 30 December 1999 an application for Marketing Authorisation 
to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  CEPROTIN,  in 
accordance with the centralised procedure falling within the scope of Part A of the Annex to Council 
Regulation No (EEC) 2309/93 of 22 July 1993, as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Dr. M. Haase 
Co-Rapporteur: 
Prof. S. Garratini 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
The procedure started on 21 January 2000. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  
4  April  2000.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
Members on 31 March 2000.  
During the CPMP meeting in May 2000 the CPMP agreed on the consolidated List of Questions 
to be sent to the company. The final consolidated List of Questions was sent to the company on 
25 May 2000. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  
25 January 2001. 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 26 February 2001.  
During the meeting on 27-29 March 2001 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to CEPROTIN on 29 March 2001. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
